|1.||Takemura, Haruyuki: 1 article (04/2013)|
|2.||Yamauchi, Takahiro: 1 article (04/2013)|
|3.||Ueda, Takanori: 1 article (04/2013)|
|4.||Negoro, Eiju: 1 article (04/2013)|
|5.||Nishi, Rie: 1 article (04/2013)|
|6.||Shajahan, Ayesha N: 1 article (01/2010)|
|7.||Clarke, Robert: 1 article (01/2010)|
|8.||Zwart, Alan: 1 article (01/2010)|
|9.||Riggins, Rebecca B: 1 article (01/2010)|
|10.||Crawford, Anatasha C: 1 article (01/2010)|
|1.||Breast Neoplasms (Breast Cancer)
11/01/2004 - "A breast cancer cell line resistant to YC137 was generated. "
01/01/2010 - "We now show the integrated roles of the antiapoptotic BCL-W and BCL2 in affecting responsiveness to the antiestrogen ICI 182,780 (ICI; Fulvestrant Faslodex), using both molecular (siRNA; shRNA) and pharmacologic (YC137) approaches in three breast cancer variants; MCF-7/LCC1 (ICI sensitive), MCF-7/LCC9 (ICI resistant), and LY2 (ICI resistant). "
11/01/2004 - "These data provide evidence for the selective killing of tumor cells by YC137 and represent the first example of in vitro selection of cancer cells refractory to a Bcl-2 inhibitor."
11/01/2004 - "We have designed and synthesized a small molecule inhibitor of Bcl-2, named YC137, and studied its role in cancer cells. "
|1.||Small Interfering RNA (siRNA)
|2.||Estrogen Receptor Modulators (Antiestrogen)